Ten life sciences companies raise about $750M in total VC money; plus public biotechs Cytomx, Sangamo draw fresh cash

The European firm’s Rafaèle Tordjman sees $1B sales, ‘exit optionality’ in a treatment for multiple lysosomal storage indications

Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules

Plus Praxis tumbles on failure in MDD and updates from Arcutis, Insilico, Alectos and more

Azafaros believes its oral dual inhibitor approach could treat lysosomal storage disorders that affect the brain